文献速递头痛与眩晕

Semont-Plus 手法与 Epley 手法治疗后半规管良性阵发性位置性眩晕:一项随机临床研究

The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo: A Randomized Clinical Study.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项前瞻性随机临床试验在3个国家转诊中心比较了 Semont-Plus 手法(SM-plus)与 Epley 手法(EM)治疗后半规管良性阵发性位置性眩晕(pcBPPV)管石症的效果。共195例患者纳入最终分析,SM-plus组至连续3个早晨无法诱发出位置性眩晕的天数均值为2.0天,EM组为3.3天(P=0.01)。SM-plus自我手法在恢复天数方面优于EM自我手法。

要点

  • SM-plus组至连续3个早晨无法诱发位置性眩晕的天数均值为2.0天,EM组为3.3天(P=0.01)。
  • 医师单次手法效果在两组间无显著差异(SM-plus组67/98[68.4%] vs EM组61/97[62.9%],P=0.42)。
  • SM-plus组24例(24.5%)、EM组19例(19.6%)出现相关恶心,两组均未检出严重不良事件。

核心结论

  • 对于后半规管良性阵发性位置性眩晕(pcBPPV)管石症,SM-plus自我手法在至恢复天数方面优于EM自我手法。

研究设计与样本

  • 前瞻性随机临床试验,在3个国家转诊中心(德国慕尼黑、意大利锡耶纳、比利时布鲁日)开展,随访至初始检查后4周,招募时间为2020年6月1日至2022年3月10日。
  • 253例患者接受资格评估,排除56例、拒绝2例,最终195例纳入分析,分析为预设的符合方案分析。
  • 患者随机分至SM-plus组或EM组,先由医师行1次初始手法,随后在家自我手法,早晨3次、中午3次、晚上3次。

主要发现

  • SM-plus组至连续3个早晨无法诱发出位置性眩晕的天数均值为2.0(1.6)天(中位数1天,范围1-8天;95%CI 1.64-2.28天)。
  • EM组至连续3个早晨无法诱发出位置性眩晕的天数均值为3.3(3.6)天(中位数2天,范围1-20天;95%CI 2.62-4.06天)(P=0.01;α=0.05,双尾Mann-Whitney检验)。
  • 医师单次手法效果(次要终点)两组间无显著差异:SM-plus组67/98(68.4%) vs EM组61/97(62.9%)(P=0.42;α=0.05)。
  • 两组均未检出严重不良事件;SM-plus组24例(24.5%)、EM组19例(19.6%)出现相关恶心。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Questions remain concerning treatment efficacy for the common condition of benign paroxysmal positional vertigo (BPPV). OBJECTIVE: To compare the effectiveness of the Semont-plus maneuver (SM-plus) and the Epley maneuver (EM) for treatment of posterior canal benign paroxysmal positional vertigo (pcBPPV) canalolithiasis. DESIGN, SETTING, AND PARTICIPANTS: This prospective randomized clinical trial was performed at 3 national referral centers (in Munich, Germany; Siena, Italy; and Bruges, Belgium) over 2 years, with a follow-up to 4 weeks after the initial examination. Recruitment took place from June 1, 2020, until March 10, 2022. Patients were selected randomly during routine outpatient care after being referred to 1 of the 3 centers. Two hundred fifty-three patients were assessed for eligibility. After consideration of the exclusion criteria as well as informed consent, 56 patients were excluded and 2 declined to participate, with 195 participants included in the final analysis. The analysis was prespecified and per-protocol. INTERVENTIONS: After being randomized to the SM-plus or the EM group, patients received 1 initial maneuver from a physician, then subsequently performed self-maneuvers at home 3 times in the morning, 3 times at noon, and 3 times in the evening. MAIN OUTCOME AND MEASURES: Patients had to document whether they could provoke positional vertigo every morning. The primary end point was the number of days until no positional vertigo could be induced on 3 consecutive mornings. The secondary end point was the effect of the single maneuver performed by the physician. RESULTS: Of the 195 participants included in the analysis, the mean (SD) age was 62.6 (13.9) years, and 125 (64.1%) were women. The mean (SD) time until no positional vertigo attacks could be induced in the SM-plus group was 2.0 (1.6) days (median, 1 [range, 1-8] day; 95% CI, 1.64-2.28 days); in the EM group, 3.3 (3.6) days (median, 2 [range, 1-20] days; 95% CI, 2.62-4.06 days) (P = .01; α = .05, 2-tailed Mann-Whitney test). For the secondary end point (effect of a single maneuver), no significant difference was detected (67 of 98 [68.4%] vs 61 of 97 [62.9%]; P = .42; α = .05). No serious adverse event was detected with both maneuvers. Nineteen patients (19.6%) in the EM group and 24 (24.5%) in the SM-plus group experienced relevant nausea. CONCLUSIONS AND RELEVANCE: The SM-plus self-maneuver is superior to the EM self-maneuver in terms of the number of days until recovery in pcBPPV. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05853328.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Strupp M, Mandala M, Vinck AS, et al. The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo: A Randomized Clinical Study. JAMA Neurol. 2023. PMID: 37358870. doi:10.1001/jamaneurol.2023.1408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。